These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 39067193)
1. Icariin protects against acute graft-versus-host disease while preserving graft-versus-leukemia activity after allogeneic hematopoietic stem cell transplantation. Su L; Wei ZF; Pi CC; Qin TX; Song F; Zhang YW; Gao SJ Phytomedicine; 2024 Sep; 132():155901. PubMed ID: 39067193 [TBL] [Abstract][Full Text] [Related]
2. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Yao Y; Wang L; Zhou J; Zhang X J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349 [TBL] [Abstract][Full Text] [Related]
3. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398 [TBL] [Abstract][Full Text] [Related]
4. IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation. Song Y; Hu B; Liu Y; Jin Z; Zhang Y; Lin D; Zhu Y; Lei L; Gong H; Mei Y; Teo HY; Wu D; Liu H Eur J Immunol; 2018 Apr; 48(4):670-682. PubMed ID: 29282719 [TBL] [Abstract][Full Text] [Related]
5. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect. Couturier M; Lamarthée B; Arbez J; Renauld JC; Bossard C; Malard F; Bonnefoy F; Mohty M; Perruche S; Tiberghien P; Saas P; Gaugler B Leukemia; 2013 Jul; 27(7):1527-37. PubMed ID: 23399894 [TBL] [Abstract][Full Text] [Related]
6. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration. Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H Front Immunol; 2021; 12():785774. PubMed ID: 34987512 [TBL] [Abstract][Full Text] [Related]
7. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice]. Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of IL-1 Receptor-Associated Kinase 1 Decreases Murine Acute Graft-versus-Host Disease While Preserving the Graft-versus-Lymphoma Effect. Gao J; Xu Y; Ma S; Liang Y; Liu C; Shen J; Sun Z; Niu M; Xu K; Pan B Transplant Cell Ther; 2022 Mar; 28(3):134.e1-134.e10. PubMed ID: 34896653 [TBL] [Abstract][Full Text] [Related]
9. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia. Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027 [TBL] [Abstract][Full Text] [Related]
11. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation. Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B Front Immunol; 2020; 11():181. PubMed ID: 32117306 [TBL] [Abstract][Full Text] [Related]
13. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677 [TBL] [Abstract][Full Text] [Related]
15. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease. García-Bernal D; Palomo M; Martínez CM; Millán-Rivero JE; García-Guillén AI; Blanquer M; Díaz-Ricart M; Sackstein R; Carreras E; Moraleda JM J Cell Mol Med; 2020 Jul; 24(14):8031-8044. PubMed ID: 32519822 [TBL] [Abstract][Full Text] [Related]
16. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. Delia M; Carluccio P; Mestice A; Chiusolo P; Metafuni E; Bellesi S; Arpinati M; Milone GA; Martino M; Mazza P; Ingrosso C; Vacca A; Saporiti G; Zallio F; Attolico I; Pastore D; Specchia G; Albano F; Musto P Transplant Cell Ther; 2021 Nov; 27(11):918.e1-918.e9. PubMed ID: 34403789 [TBL] [Abstract][Full Text] [Related]
17. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice. Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029 [TBL] [Abstract][Full Text] [Related]
18. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation. Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241 [TBL] [Abstract][Full Text] [Related]
19. A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model. Bäuerlein CA; Riedel SS; Baker J; Brede C; Garrote AL; Chopra M; Ritz M; Beilhack GF; Schulz S; Zeiser R; Schlegel PG; Einsele H; Negrin RS; Beilhack A BMC Med; 2013 May; 11():134. PubMed ID: 23692886 [TBL] [Abstract][Full Text] [Related]
20. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]